N-(5-methylpyridin-2-yl)cyclopropanecarboxamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-methylpyridin-2-yl)cyclopropanecarboxamide
• 化学式: C₁₀H₁₂N₂O
• mdl: MFCD02147569
• 分子量: 176.21
• InChiKey: LCGXJVSHRUGFRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS INCLUDING MAP KINASE INTERACTING KINASES 1 AND 2 (MNK1 AND MNK2) MODULATORS AND ABL AND ABL (T315I) INHIBITORS, AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT DES MODULATEURS DES KINASES INTERAGISSANT AVEC LES MAP KINASES 1 ET 2 (MNK1 ET MNK2) ET DES INHIBITEURS D'ABL ET ABL (T315I), ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2014088519A1

  公开（公告）日：2014-06-12

  The present invention relates to certain piperazine-based compounds that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b and/or as ABL or ABL (T315I) inhibitors. The invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of cancer, inflammatory and Alzheimer disease conditions, as well as methods of treatment of these disorders.

  本发明涉及某些基于哌嗪的化合物，其作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂，和/或作为ABL或ABL（T315I）抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗癌症、炎症和阿尔茨海默病等疾病症状的药物的用途，以及治疗这些疾病的方法。
• PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS
  申请人：DOMAINEX LIMITED

  公开号：US20160000784A1

  公开（公告）日：2016-01-07

  Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1 in which one of V and W is N, and the other of V and W is C—H; and R 1 , R 2 , R 3 and R 4 are as defined in the specification. The invention also provides uses of the compounds and compositions containing them.

  通式（I）及其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病方面具有用处，其中V和W中的一个是N，另一个是C-H；R1、R2、R3和R4如规范中定义。本发明还提供了化合物的用途和含它们的组合物。
• HETEROARYLAMIDE INHIBITORS OF TBK1
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20170313675A1

  公开（公告）日：2017-11-02

  Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.
• US9433622B2
  申请人：——

  公开号：US9433622B2

  公开（公告）日：2016-09-06
• US9994547B2
  申请人：——

  公开号：US9994547B2

  公开（公告）日：2018-06-12